

ASAS activiteiten 2020

I. Organisatie van workshops

- 17 en 18 januari 2020: Houston, USA. jaarlijkse ASAS internationale workshop en algemene vergadering

II. Toekennen van beurzen

ASAS Grant 2020

- Faten Hamitouche, Parijs, Frankrijk:

“Determinants of clinically important worsening in early axial SpA”

-Katharina Ziegeler, Berlijn, Duitsland

“Anatomic variation of the sacroiliac joints”

-Stan Kieskamp, Groningen, Nederland

“Exploring the Interrelationships between Central Sensitization, Disease Perceptions, Coping strategies and Disease activity in patients with axial Spondyloarthritis”

ASAS fellowship 2020

-Para Kamrcharya, San Francisco, USA

“Accumulation of Comorbidities and Association with Disease Activity and Functional Impairment in Ankylosing Spondylitis: data from the PSOAS cohort”

III. Organisatie van globale onderzoeksprojecten

-1^e patiënten geïncubeerd in de wereldwijde ASAS Classification of Axial Spondyloarthritis Inception Cohort (CLASSIC) cohort

-initiatie van de ASAS-SPARTAN Axial Involvement In Psoriatic Arthritis Cohort (AXIS)

-update van de ASAS core set: goedkeuring van de “core domains” door OMERACT in november 2020

- ASAS PerSpA studie afgerond en publicatie van de resultaten (PMID: 33462157)

-ASAS slide library update

-update van de ASAS app met alle talen die ook gebruikt worden in de ASAS slide library

IV. Inkomsten via Corporate partnerships

- Platinum Corporate Partners: Abbvie, Pfizer, UCB

- Gold Corporate Partners: Janssen, Novartis, Eli Lilly



ASAS activities 2020

I. Organization of workshops

- January 17th and 18th, 2020: Houston, USA. annual ASAS international workshop and general meeting

II. Granting of grants

ASAS Grant 2020

- Faten Hamitouche, Paris, France

“Determinants of clinically important worsening in early axial SpA”

-Katharina Ziegeler, Berlin, Germany

“Anatomic variation of the sacroiliac joints”

-Stan Kieskamp, Groningen, The Netherlands

“Exploring the Interrelationships between Central Sensitization, Disease Perceptions, Coping strategies and Disease activity in patients with axial Spondyloarthritis”

ASAS fellowship 2020

-Para Kamrcharya, San Francisco, USA

“Accumulation of Comorbidities and Association with Disease Activity and Functional Impairment in Ankylosing Spondylitis: data from the PSOAS cohort”

III. Organization of global research projects

-1st patients enrolled in the global ASAS Classification or Axial Spondyloarthritis Inception Cohort (CLASSIC) cohort

-initiation of the ASAS-SPARTAN Axial Involvement In Psoriatic Arthritis Cohort (AXIS)

-update of the ASAS core set with approval of the core domains by OMERACT in November 2020

- ASAS PerSpA study completed and publication of results (PMID: 33462157)

-ASAS slide library update

-update of the ASAS app with all languages that are also used in the ASAS slide library

IV. Income through Corporate partnerships

- Platinum Corporate Partners: Abbvie; Pfizer, UCB

- Gold Corporate Partners: Janssen, Novartis, Eli Lilly